IMVT — Immunovant, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1764013 ·
Last close
$30.26
Market Cap
$6.25B
52W High
$45.42
52W Low
$16.08
ADV30
1,471,417
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -160,323,000 | -153,224,000 | 852,490,000 | 797,798,000 | 117,102,000 |
| Mar 2026 | — | — | — | — | — | — | — |
| Dec 2025 | 0 | — | -114,362,000 | -110,635,000 | 1,052,392,000 | 994,525,000 | 66,257,000 |
| Sep 2025 | 0 | — | -131,762,000 | -126,502,000 | 582,959,000 | 521,870,000 | 63,254,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-414,304,000
Investing CF
$-8,000
Financing CF
$612,935,000
CapEx
$-381,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.82
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,898,353,000
Inventory
—
Receivables
$697,000
ST Investments
—
EBIT TTM
$-566,001,000
Pretax Income TTM
$-538,915,000
Interest Exp TTM
—
Analysts
15
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | -532,902,000 | -505,606,000 | 957,014,000 | 104,422,000 | 852,592,000 | -407,310,000 |
| Mar 2025 | 0 | -438,152,000 | -413,840,000 | 776,222,000 | 68,775,000 | 707,447,000 | -375,874,000 |
| Mar 2024 | 0 | -270,209,000 | -259,336,000 | 666,365,000 | 48,608,000 | 617,757,000 | -214,227,000 |
| Mar 2023 | 0 | -208,276,000 | -210,960,000 | 405,838,000 | 43,344,000 | 362,494,000 | -188,193,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
$-505,606,000
OpCashFlow TTM
—
Assets (Latest)
$1,052,392,000
Forward EPS
$-2.75
Max Pain — expiry 2026-12-18
max pain strike: $30.00 · spot: $30.26 · call oi: 10,081 · put oi: 371
Expected Move to 2026-12-18:
±$16.60
(54.86%) —
implied range
$13.66 –
$46.86
· ATM straddle on $30.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IOVA | IOVANCE BIOTHERAPEUTICS, INC. | $6.03B | $13.31 | — |
| KOD | Kodiak Sciences Inc. | $5.92B | $94.26 | — |
| CGON | CG Oncology, Inc. | $5.61B | $63.26 | — |
| SRRK | Scholar Rock Holding Corp | $5.14B | $42.20 | — |
| CRSP | CRISPR Therapeutics AG | $4.88B | $50.44 | — |
News headlines (Yahoo Finance, 1h cache)
IMVT, ROIV Stocks Slide As Argenx Sjögren’s Trial Failure Hits Drug Class
2026-10-08 17:33 · Yahoo
Why Immunovant (IMVT) Is Down 10.3% After Halting IMVT-1402 Development in Cutaneous Lupus – And What's Next
2026-09-30 06:06 · Yahoo
Immunovant (IMVT) Just Gave Investors Something To Think About
2026-09-29 02:07 · Yahoo
Immunovant (IMVT): One Trial Failure Doesn’t Break the Bull Case
2026-09-27 14:40 · Yahoo
Lilly’s latest China drug deal; Immunovant’s setback in lupus
2026-09-24 14:14 · Yahoo
Roivant reports top-line data from IMVT-1402 CLE trial
2026-09-24 09:32 · Yahoo
Immunovant Stock Slides After Biotech Scraps Autoimmune Drug Program
2026-09-23 17:44 · Yahoo
Immunovant Pulls Plug On Lupus Program After Study Misses Primary Goal — IMVT Stock Heads For Over 3-Month Lows
2026-09-23 12:32 · Yahoo
Roivant’s Immunovant Stops IMVT-1402 Development in Cutaneous Lupus After Trial Miss
2026-09-23 12:12 · Yahoo
Immunovant Shares Fall 6% After IMVT-1402 Lupus Study Misses Primary Endpoint
2026-09-23 12:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.